UK Regulator Says April Fee Rise Will Support 'Innovative & Efficient' Service
The Medicines and Healthcare products Regulatory Agency says that the fee increases to be introduced on 1 April, along with 18 new fees, are necessary for its long-term financial sustainability and its ability to provide a “responsive, innovative and efficient regulatory service.”
You may also be interested in...
UK Regulator Plans New & Higher Fees To Ensure Financial Sustainability
The MHRA says pharmaceutical and medical device companies should be confident that planned changes to the fees structure will guarantee them “the high-quality service they expect.”
UK Regulator To Lose 20% Of Staff In Post-Brexit Cost-Cutting Plans
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.